Canaccord Genuity Reiterates a 'Hold' on XOMA, Ltd. (XOMA); Q4/11: Gevokizumab Development Rolls On
Tweet
Share
E-mailGet Alerts XOMA Hot Sheet
Price: $40.17 --0%
Rating Summary:
4 Buy, 10 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 14 | Down: 11 | New: 36
Rating Summary:
4 Buy, 10 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 14 | Down: 11 | New: 36
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Hold' on XOMA, Ltd. (NASDAQ: XOMA) price target of $2.00.
Analyst, Ritu Baral, said, "Reiterate rating and price target on gevokizumab potential in non-infectious uveitis and cardiovascular. Phase 2a and Phase 2b CRP reduction data suggest 052’s promise in CV. Early clinical data indicates 052’s potential benefit in Behcet’s and non-infectious uveitis, but final pivotal trial design will be critical for success."
"We view gevokizumab uveitis program as XOMA’s most valuable asset; Phase 3 NIU trial to start Q2/12. Data from XOMA’s US non-infectious uveitis trial is expected H2/13. Servier will run the ex-US Bechet’s uveitis Phase 3 trial."
For an analyst ratings summary and ratings history on XOMA, Ltd. click here. For more ratings news on XOMA, Ltd. click here.
Shares of XOMA, Ltd. closed at $1.96 yesterday.
Analyst, Ritu Baral, said, "Reiterate rating and price target on gevokizumab potential in non-infectious uveitis and cardiovascular. Phase 2a and Phase 2b CRP reduction data suggest 052’s promise in CV. Early clinical data indicates 052’s potential benefit in Behcet’s and non-infectious uveitis, but final pivotal trial design will be critical for success."
"We view gevokizumab uveitis program as XOMA’s most valuable asset; Phase 3 NIU trial to start Q2/12. Data from XOMA’s US non-infectious uveitis trial is expected H2/13. Servier will run the ex-US Bechet’s uveitis Phase 3 trial."
For an analyst ratings summary and ratings history on XOMA, Ltd. click here. For more ratings news on XOMA, Ltd. click here.
Shares of XOMA, Ltd. closed at $1.96 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Coinbase (COIN) PT Raised to $212 at Cantor Fitzgerald
- AutoZone (AZO) PT Lowered to $3,500; TD Cowen: 'Strong Execution But Not Immune To Industry DIY Headwinds'
- Freedom Broker Downgrades STRATTEC Security (STRT) to Hold
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
